Table 2.
Selected clinical trials using ALK inhibitors
| Therapeutic | Target(s) | Phase | Identifier* |
|---|---|---|---|
| Alectinib (CH5424802) | ALK | III | NCT02075840 |
| AP26113 | ALK/EGFR | I/II | NCT01449461 |
| TSR-001 | ALK/TRK | I/IIa | NCT02048488 |
| X-396 | ALK | I | NCT01625234 |
| CEP-37440 | ALK/FAK | I | NCT01922752 |
| Ganetespib (STA-9090) | Hsp90 | I/II | NCT01579994 |
| III | NCT01798485 | ||
| AP36113 | ALK/EGFR | I/II | NCT01449461 |
| AUY992 | Hsp90 | II | NCT01752400 |
| AT13387 | Hsp90 | I/II | NCT01712217 |
| DS-2248 | Hsp90 | I | NCT01288430 |
Note:
*
Identifier from ClinicalTrials.gov.
Abbreviations: ALK, anaplastic lymphoma receptor tyrosine kinase; EGFR, epidermal growth factor receptor; Hsp90, heat shock protein 90.